Vyzulta Alternatives Compared
| Vyzulta (latanoprostene bunod) | Combigan (brimonidine / timolol) | Zioptan (tafluprost) |
|
|---|
| Vyzulta (latanoprostene bunod) | Combigan (brimonidine / timolol) | Zioptan (tafluprost) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Glaucoma - Open Angle, Glaucoma/Intraocular Hypertension. Vyzulta may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Glaucoma/Intraocular Hypertension, Glaucoma, Intraocular Hypertension. Combigan may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Glaucoma - Open Angle, Glaucoma/Intraocular Hypertension, Intraocular Hypertension. Zioptan may also be used for purposes not listed in this medication guide. |
Related suggestions Glaucoma/Intraocular Hypertension
|
|||||||||||||||||||||||
| More about Vyzulta (latanoprostene bunod) | More about Combigan (brimonidine / timolol) | More about Zioptan (tafluprost) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Vyzulta has an average rating of 6.4 out of 10 from a total of 12 ratings on Drugs.com. 58% of reviewers reported a positive effect, while 33% reported a negative effect. |
Combigan has an average rating of 4.9 out of 10 from a total of 25 ratings on Drugs.com. 40% of reviewers reported a positive effect, while 48% reported a negative effect. |
Zioptan has an average rating of 5.9 out of 10 from a total of 14 ratings on Drugs.com. 43% of reviewers reported a positive effect, while 36% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Vyzulta side effects |
View all Combigan side effects |
View all Zioptan side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Vyzulta prices |
View all Combigan prices |
View all Zioptan prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
N/A |
7 hours |
N/A |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 7 drugs are known to interact with Vyzulta:
|
A total of 548 drugs are known to interact with Combigan:
|
A total of 6 drugs are known to interact with Zioptan:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
|
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
N/A |
October 30, 2007 |
N/A |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.